Competition radioligand binding assays for the investigation of bispyridinium compound affinities to the human muscarinic acetylcholine receptor subtype 5 (hM5)

Drug Testing and Analysis

Volumn 4, Issue 3-4, 2012, Pages 292-297

  Niessen, K V ^a   Tattersall, J E H ^b   Timperley, C M ^b   Bird, M ^b   Green, C ^b   Thiermann, H ^a   Worek, F ^a  

^a BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Bispyridinium compound; Muscarinic acetylcholine receptor; Radioligand binding assay

Indexed keywords

BINDING ASSAYS; BINDING-SITES; BISPYRIDINIUM COMPOUND; MICROMOLAR RANGE; MUSCARINIC ACETYLCHOLINE RECEPTORS; MUSCARINIC RECEPTOR; NERVE AGENTS; RADIOLIGAND BINDING; RADIOLIGAND BINDING ASSAY; THERAPEUTIC EFFICACY;

ASSAYS;

BIS(4 TERT BUTYL 1 PYRIDINIOMETHYL) ETHER; BISPYRIDINIUM COMPOUND; MUSCARINIC M5 RECEPTOR; NICOTINIC RECEPTOR; PYRIDINIUM DERIVATIVE; RADIOLIGAND; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTOXICATION; MEDICAL RESEARCH; PRIORITY JOURNAL; RADIOASSAY;

EID: 84859432802     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.410     Document Type: Article

References (55)

1. M. P. Caulfield Muscarinic receptors - Characterization, coupling and function. Pharmacol. Therapeut. 1993, 58, 319.
2. R. S. Aronstam, T. K. Narayanan Temperature effect on the detection of muscarinic receptor-G protein interactions in ligand binding assays. Biochem. Pharmacol. 1988, 37, 1045.
3. M. P. Caulfield, N. J. M. Birdsall International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998, 50, 279.
4. 5 receptor: a silent or emerging subtype? Brit. J. Pharmacol. 2000, 130, 13.
5. T. A. Slotkin, F. J. Seidler Comparative developmental neurotoxicity of organophosphates in vivo: transcriptional responses of pathways for brain cell development, cell signalling, cytotoxicity and neurotransmitter systems. Brain Res. Bull. 2007, 72, 232.
6. 5 receptor single knockout mice. Brit. J. Pharmacol. 2009, 156, 1147.
7. 5 muscarinic acetylcholine receptor knockout mice. P. Natl Acad. Sci. USA 2001, 98, 14096.
8. K. Schoene, H. Oldiges Die Wirkungen von Pyridiniumsalzen gegenüber Tabun- und Sarinvergiftungen in vivo und in vitro. Arch. Int. Pharmacodyn. 1973, 204, 110.
9. L. W. Harris, W. C. Heyl, D. L. Siltcher, C. A. Broomfield Effects of 1, 1'-oxidimethylene bis-(4-tert-butylpyridinium chloride) (SAD-128) and decamethonium on reactivation of soman- and sarin-inhibited cholinesterase by oximes. Biochem. Pharmacol. 1978, 27, 757.
10. A. Štalc, M. Šentjurc A contribution to the mechanism of action of SAD-128. Biochem. Pharmacol. 1990, 40, 2511.
11. M. Alkondon, E. X. Albuquerque The nonoxime bispyridinium compound SAD-128 alters the kinetic properties of the nicotinic acetylcholine receptor ion channel: a possible mechanism for antidotal effects. J. Pharmacol. Exp. Ther. 1989, 250, 842.
12. Z. Grubič, A. Tomažič Mechanism of action of HI-6 on soman inhibition of acetylcholinesterase in preparation of rat and human skeletal muscle; comparison to SAD-128 and PAM-2. Arch. Toxicol. 1989, 63, 68.
13. J. E. H. Tattersall Ion channel blockade by oximes and recovery of diaphragm muscle from soman poisoning in vitro. Brit J. Pharmacol. 1993, 108, 1006.
14. M. H. B. Cid, U. Holzgrabe, E. Kostenis, K. Mohr, C. Tränkle Search for the pharmacophore of bispyridinium-type allosteric modulators of muscarinic receptors. J. Med. Chem. 1994, 37, 1439.
15. C. Tränkle, E. Kostenis, U. Burgmer, K. Mohr Search for lead structures to develop new allosteric modulators of muscarinic receptors. J. Pharmacol. Exp. Ther. 1996, 279, 926.
16. U. Sürig, K. Gaal, E. Kostenis, C. Tränkle, K. Mohr, U. Holzgrabe Muscarinic allosteric modulators. Atypical structure-activity-relationships in bispyridinium-type compounds. Arch. Pharm. Chem. Life Sci. 2006, 339, 207.
17. 5 chimeric receptors. Mol. Pharmacol. 2005, 68, 1597.
18. 5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol. Pharmacol. 2003, 64, 21.
19. 5 muscarinic acetylcholine receptor genes. Neuron 1988, 1, 403.
20. N. J. Buckley, T. I. Bonner, C. M. Buckley, M. R. Brann Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol. Pharmacol. 1989, 35, 469.
21. M. Jolkkonen, P. L. M. van Giersbergen, U. Hellman, C. Wernstedt, E. Karlsson A toxin from the green mamba Dendroaspis angusticeps; amino acid sequence and selectivity for muscarinic m4 receptors. FEBS Lett. 1994, 352, 91.
22. 5 muscarinic receptor subtypes in mammalian cells. Biotechnol. Lett. 2006, 28, 121.
23. S. Z. Wang, E. E. El-Fakahay Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists. J. Pharmacol. Exp. Ther. 1993, 266, 237.
24. T. M. Cembala, J. D. Sherwin, M. D. Tidmarsh, B. L. Appadu, D. G. Lambert Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Brit. J. Pharmacol. 1998, 125, 1088.
25. K. Cheng, S. Khurana, Y. Chen, R. H. Kennedy, P. Zimniak, J. P. Raufman Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J. Pharmacol. Exp. Ther. 2002, 303, 29.
26. 5 muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 1995, 274, 1077.
27. J. Jabubík, H. Janíčková, E. E. El-Fakahany, V. Doležal Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy. Brit. J. Pharmacol. 2011, 162, 1029.
28. C. M. Timperley, M. Bird, S. C. Heard, S. Notman, R. W. Read, J. E. H. Tattersall, S. R. Turner Fluorinated pyridine derivatives. Part 1. The synthesis of some mono- and bis-quaternary pyridine salts of potential use in the treatment of nerve agent poisoning. J. Fluorine Chem. 2005, 126, 1160.
29. S. R. Turner, J. E. Chad, M. Price, C. M. Timperley, M. Bird, A. C. Green, J. E. H. Tattersall Protection against nerve agent poisoning by a noncompetitive nicotinic antagonist. Toxicol. Lett. 2011, 206, 105.
30. 3 receptor. Brit. J. Pharmacol. 2006, 148, 927.
31. R. F. Bruns, K. Lawson-Wendling, T. A. Pugsley A rapid filtration assay for soluble receptors using polyethylenimine-treated filters. Anal. Biochem. 1983, 132, 74.
32. 3H]methylscopolamine to glass fibre filters. J. Pharm. Pharmacol. 1987, 39, 239.
33. C. M. Scaramellini-Carter, J. R. Leighton-Davies, S. J. Charlton Miniaturized receptor binding assays: complications arising from ligand depletion. J. Biomol. Screen. 2007, 12, 255.
34. G. E. Rovati Rational experimental design and data analysis for ligand binding studies: tricks, tips and pitfalls. Pharmacol. Res. 1993, 28, 277.
35. P. K. Smith, R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, D. C. Klenk Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150, 76.
36. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099.
37. N. J. M. Birdsall, A. S. V. Burgen, E. C. Hulme The binding of agonists to brain muscarinic receptors. Mol. Pharmacol. 1978, 14, 723.
38. G. A. Weiland, P. B. Molinoff Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties. Life Sci. 1981, 29, 313.
39. 3-receptor antagonists can be thermodynamically discriminated. Brit. J. Pharmacol. 2007, 151, 504.
40. 2+, guanine nucleotides, and monovalent cations. Mol. Pharmacol. 1985, 28, 400.
41. 5 cholinoceptors. Life Sci. 1999, 64, 557.
42. F. Dörje, J. Wess, G. Lambrecht, R. Tacke, E. Mutschler, M. R. Brann Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 1991, 256, 727.
43. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Brit. J. Pharmacol. 1997, 20, 1409.
44. 5 using microphysiometry. Brit J. Pharmacol. 1999, 126, 1620.
45. F. Huang, P. Buchwald, C. E. Browne, H. H. Farag, W.-M. Wu, F. Ji, G. Hochhaus, N. Bodor Receptor binding studies of soft anticholinergic agents. AAPS J. 2001, 3, 44.
46. J. Jakubík, L. Bačáková, E. E. El-Fakahany, S. Tuček Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 1997, 52, 172.
47. 1 muscarinic acetylcholine receptor. Mol. Pharmacol. 1998, 53, 1120.
48. E. G. Peralta, A. Ashkenazi, J. W. Winslow, D. H. Smith, J. Ramachandran, D. J. Capon Distinct primary structures, ligand binding properties and tissue-specific expression of four human acetylcholine receptors. EMBO J. 1987, 6, 3923.
49. 5 muscarinic receptors expressed in CHO-K1 cells. Brit. J. Pharmacol. 1999, 127, 590.
50. 5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. J. Med. Chem. 2009, 52, 3445.
51. K. V. Niessen, J. E. H. Tattersall, C. M. Timperley, M. Bird, C. Green, T. Seeger, H. Thiermann, F. Worek Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs). Toxicol. Lett. 2011, 206, 100.
52. A. Christopoulos, T. Kenakin G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 2002, 54, 323.
53. T. Disingrini, M. Muth, C. Dallanoce, E. Barocelli, S. Bertoni, K. Kellershohn, K. Mohr, M. De Amici, U. Holzgrabe Design, synthesis and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J. Med. Chem. 2006, 49, 366.
54. J. Antony, K. Kellershohn, M. Mohr-Andrä, A. Kebig, S. Prilla, M. Muth, E. Heller, T. Disingrini, C. Dallanoce, S. Bertoni, J. Schrobang, C. Tränkle, E. Kostenis, A. Christopoulos, H.-D. Höltje, E. Barocelli, M. De Amici, U. Holzgrabe, K. Mohr Dualsteric GPCR targeting: a novel route to binding and signalling pathway selectivity. FASEB J. 2009, 23, 442.
55. N. T. Burford, J. Watson, R. Bertekap, A. Alt Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem. Pharmacol. 2011, 81, 691.